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Genomic instabilityThe identiﬁcation of SYK as amolecular target in B-lineage leukemia/lymphoma cells prompted the development
of SYK inhibitors as a new class of anti-cancer drug candidates. Herewe report that induction of the SYK gene ex-
pression in human cells causes a signiﬁcant down-regulation of evolutionarily conserved genes associated with
mitosis and cell cycle progression providing unprecedented evidence that SYK is a master regulator of cell cycle
regulatory checkpoint genes in human cells. We further show that SYK regulates the G2 checkpoint by physically
associatingwith and inhibiting the dual-speciﬁcity phosphatase CDC25C via phosphorylation of its S216 residue.
SYK depletion by RNA interference or treatment with the chemical SYK inhibitor prevented nocodazole-treated
human cell lines from activating theG2 checkpoint via CDC25C S216-phosphorylation and resulted in polyploidy.
Our study provides genetic and biochemical evidence that spleen tyrosine kinase (SYK) has a unique role in the
activation of the G2 checkpoint in both non-lymphohematopoietic and B-lineage lymphoid cells. This previously
unknown role of SYK as a cell cycle checkpoint regulator represents an unforeseen and signiﬁcant challenge for
inhibitors of SYK ATP binding site.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
CDC25C is a dual speciﬁcity phosphatase that controls entry intomi-
tosis (viz.: prophase to metaphase transition) by dephosphorylating
p34cdc2/CDK1 on threonine 14 (T14) and tyrosine 15 (Y15) and thereby
activating the CDK1/cylin B complex, also known as themitosis promot-
ing factor (MPF), at the end of G2 (Kiyokawa and Ray, 2008; Perry and
Kornbluth, 2007; Donzelli and Draetta, 2003). S216 phosphorylation
of CDC25C has been shown to inhibit its MPF-activating function in
the nucleus by enhancing its binding to 14-3-3 proteins and thereby
causing its sequestration in the cytoplasm (Kumagai and Dunphy,
1999). CDC25C is a key element of the G2 checkpoint pathway that de-
lays entry into mitosis in response to DNA damage or microtubule-
destabilizing agents such as nocodazole (NOC). In most species, the G2
checkpoint prevents CDC25C phosphatase from removing the T14/Y15
phosphate groups on CDK1 and thereby provides more time for DNAg ﬁnancial interests.
dicine, Smith Research Tower
27-0367, USA.
. This is an open access article underdamage repair. This is accomplished by maintaining CDC25C in a phos-
phorylated form on its critical S216 residue in humans and the corre-
sponding S287 residue in Xenopus (Kiyokawa and Ray, 2008). The
checkpoint kinases, CHK1 and CHK2 are known to phosphorylate
CDC25C on its S216 residue (Kiyokawa and Ray, 2008; Perry and
Kornbluth, 2007). While some kinases, including PKA, C-TAK, and
CAMKII have been shown to phosphorylate S287, they are not regulated
by cell cycle checkpoints (Kiyokawa and Ray, 2008; Peng et al., 1998;
Duckworth et al., 2002; Hutchins et al., 2003). It is generally assumed
that additional G2 checkpoint kinases must exist but their identities
have not yet been deciphered (Kiyokawa and Ray, 2008).
Spleen tyrosine kinase (SYK) is a physiologically important kinase
that serves as a key regulator of multiple biochemical signal transduc-
tion events and biologic responses (Cheng et al., 1995; Mocsai et al.,
2010; Turner et al., 1997; Uckun and Qazi, 2010; Zhou et al., 2006;
Goodman et al., 2001; Heizmann and Reth, 2010; Wang et al., 2005;
Uckun et al., 2010a,b, 2012; He et al., 2002). We now provide new ge-
netic and biochemical evidence that SYK is an inhibitor of CDC25C in
B-lineage lymphoid cells as well as non-lymphohematopoietic cells,
that prevents premature entry into mitosis by phosphorylating
CDC25C at S216 when G2 checkpoint responses are activated.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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2.1. Standard Biochemical, Imaging, and Transfection Methods
Confocal Laser Scanning Microscopy, co-immunoprecipitations,
kinase assays, Western blot analyses, and gel ﬁltration were performedFig. 1. Subcellular localization of GFP-tagged recombinant rat SYK protein in transfectedU373 h
transfected with pEGFP-SYK plasmid (but not the whole cell lysates of untransfected U373 cells
sion of a 99-kDa GFP-SYK fusion protein. [b] Immune complex kinase assays using monoclonal
nous SYK kinase substrate conﬁrmed the kinase activity of GFP-SYK expressed inU373 cells. Pur
included as a control. Two bands (marked with arrowheads) were identiﬁed in the kinase reac
corresponds to autophosphorylation of GFP-tagged SYK and the other corresponds to phosphor
autophosphorylation and phosphorylated GST-Igα in the control kinase reaction. [c–e] Whe
ﬂuorescent GFP-tagged SYK localized as a single focus on each side of themetaphase plate to the
easily identiﬁed by TOTO-3 stained (Blue) chromosomal DNA aligned on themetaphase plate (s
monoclonal anti-Tubulin antibody.Merge confocal images depicting centrosomal localization of
two representative metaphase cells. During metaphase, there is a single SYK focus localized to
cells. SYK staining in perinuclear centrioles is observed as two bright foci adjacent to the nucle
stained DNA/chromosomes (system magniﬁcation, 250×).as per previously described standard procedures (Uckun et al., 2010a,b,
2012) (Supplemental information). 293T cells were transfected after
reaching 70–80% conﬂuence using ON-TARGETplus SMARTpool siRNA
and DharmaFECT Transfection Reagent 4 (Catalog No. T-2004) (Thermo
Scientiﬁc Dharmacon, Lafayette, CO, USA). The SYK phosphorylation
site of CDC25C was determined by matrix-assisted laser desorption/uman glioblastoma cells. [a.1 & a.2]Western blot analysis ofwhole cell lysates of U373 cells
) with anti-SYK (Panel a.1) or anti-GFP (Panel a.2) antibodies conﬁrmed abundant expres-
anti-GFP antibody for immunoprecipitation of GFP-tagged SYK and GST-Igα as an exoge-
iﬁedmurine SYK protein together with GST-Igα as an exogenous SYK kinase substrate was
tion mixture containing immunoprecipitates from pEGFP-SYK transfected cells. One band
ylation of GST-Igα byGFP-tagged SYK. Likewise, puriﬁed recombinantmurine SYK showed
n TOTO-3 stained transfected cells were analyzed by deconvolution microscopy, green-
mitotic spindle poles aswell as spindle ﬁbers inmitotic cells (d:metaphase, e: anaphase),
ystemmagniﬁcation, 500×). [f & g] TransfectedU373 cells were stainedwith TOTO-3 and a
GFP-tagged SYK are shown for interphase as well asmetaphase cells. Panel f: Depicted are
the centrosome at each spindle pole. Panel g: Depicted are two representative interphase
us in interphase U373 cells. Green = GFP-tagged SYK; red = α-Tubulin; blue = TOTO-3
18 F.M. Uckun et al. / EBioMedicine 1 (2014) 16–28ionization–time-of-ﬂight (MALDI-TOF/TOF) mass spectrometry follow-
ing a standard protocol (Supplemental information).
2.2. Molecular Model of SYK–CDC25C Interaction
A structural model of SYK–CDC25C peptide complex was construct-
ed based on the ternary complex structure of PhKwith MC peptide and
then minimized using the Amber forceﬁeld. While the structure of theC-terminal catalytic domain of CDC25C is known (PDB 3op3), the
N-terminus, including the region corresponding to residues 211 to
219, does not have a known structure. Chen et al. built a kinase–sub-
strate peptide model for the interaction of Chk1 with the human
CDC25C peptide LYRSPSMPE (residue 211–219) based on the ternary
complex structure of glycogen phosphorylase kinase (PhK) with a
“Modiﬁed Cantley” (MC) peptide RQMSFRL (Chen et al., 2000). Using
amodiﬁcation of their reported strategy, we built amodel for the binary
SYK–CDC25C peptide complex. Speciﬁcally, we ﬁrst superimposed the
main-chain atoms of the crystal structure of the PhK–MC peptide
complex (PDB entry: 2PHK) (Chen et al., 2000) and the apo SYK tyrosine
kinase domain (PDB entry: 1XBA) (Atwell et al., 2004) using Sybyl6.8
(Tripos, St. Louis, MO). The MC peptide positioned in the superimposed
SYK catalytic site, was then used as a template for “grafting” the
7-amino acid CDC25C peptide RSPSMPE, residues 213–219 (the
underlined residue represents the predicted phosphorylation site) in
backbone conformation into the SYK catalytic site according to the
following sequence alignment, as previously reported by Chen et al.
(2000).
MC Peptide RQMSFRL
CDC25 Peptide RSPSMPE
An initial model of the SYK–CDC25C complex was obtained by ran-
domly selecting the positions for CDC25C residues Tyr212 and Leu211
from the N-terminal of CDC25C Arg213 residue through residueFig. 2. Induction of SYK gene expression causes down-regulation of cell cycle genes asso-
ciated with G2/M transition. [a & b] Gene set enrichment analysis. Rank ordered T-values
for SYK induced samples (red to blue up regulated to down regulated respectively)
were processed for enrichment of Biological Process Gene Ontology terms using a super-
vised approach implemented inGSEA2.08 (Broad institute). Highly signiﬁcant correlations
(FDR b 0.0001) were observed for genes that were down regulated following SYK induc-
tion (hits shown by black lines on the graph) and annotations for “Mitotic Cell cycle”
(a: Gene Set size = 112) and “Cell Cycle (GO 0007049)” (b: Gene Set size = 226). [c–e]
SYK induction causes down-regulation of genes that exhibit peak expression in G2/M
phases of the yeast cell cycle. Thedown-regulatedgenes in SYK-inducedU373 cells includ-
ed the human homologs of ﬁve yeast genes (viz.: CDC20, TAL1, PGM2, DBF4, BUB3) previ-
ously demonstrated to have peak expression in the G2 andMphases of the yeast cell cycle.
Genome-wide gene expression data from highly synchronized yeast cultures were cross-
referencedwith humanhomologs of genes down-regulated by SYK induction inU373 cells
(GSE18798). Five yeast genes exhibited primary peaks of expression at G2/M transition
and in M-phase (c) depicted on the color-coded scaled diagram relating cell cycle phases
and expression peaks (http://moment.utmb.edu/cgi-bin/timing_main.cgi). Human homo-
logs of these yeast cell cycle genes were down-regulated in SYK-induced U373 cells (d).
CDC20 (8.4 fold decrease) was the most signiﬁcantly down-regulated yeast G2/M gene
(e). [f & g] SYK induction causes down-regulation of human homologs of ATM-dependent
mouse G2/M checkpoint genes. Previously published global gene expression data
(GSE11436) in thymocytes harvested from wildtype and ATM−/− mice were compared
to identify ionizing radiation (IR)-responsive genes that are ATM-dependent. Rank
ordered T-values for SYK induced samples (red to blue up regulated to down-regulated
respectively) were processed for enrichment of downstream targets of ATM in irradiated
mice. f: The group of genes that were down-regulated in ATM−/− cells was over-repre-
sented for mouse homologs of genes that were up-regulated with SYK induction
(FDR = 0.0029; Gene set size = 388 genes). g: Conversely, the group of up-regulated
genes in irradiated ATM−/− cells was highly enriched for mouse homologs of genes that
were down-regulated after SYK induction (FDR b 0.0001; Gene Set size = 235 genes).
[h & i] SYK induction causes down-regulation of ATM-dependent human radiation re-
sponse genes. Rank-ordered fold difference values from the comparison of irradiated
wildtype and ATM−/−mouse thymocytes (red indicates up-regulation and blue indicates
down-regulation in ATM−/− cells) and rank-ordered T-values for SYK-induced samples
(red to blue: up-regulated to down-regulated) were processed for enrichment of down-
stream targets of human ATM. h: Radiation responsive human ATM targets (down-
regulated in irradiated WT compared to irradiated ATM mutant human lymphoblasts)
were overrepresented in genes up-regulated in irradiated thymocytes from ATM−/−
mice (P-value b 0.001, FDR b 0.001; probe set size = 52 Affymetrix Mouse 430A_2 gene
chip probe sets representing 40 human orthologs). i: Radiation-responsive human ATM
targets (down-regulated in irradiated WT compared to irradiated ATM mutant human
lymphoblasts) were overrepresented in genes that were down-regulated after SYK induc-
tion (P-value = 0.016, FDR = 0.041; gene set size = 36 genes represented on the
Affymetrix U95 Av2 genechip).
19F.M. Uckun et al. / EBioMedicine 1 (2014) 16–28conformational search encoded in the “Biopolymers” module of
Sybyl6.8 and modeling the 9-amino acid CDC25C peptide (sequence
LYRSPSMPE, residues 211–219) as a substrate in the SYK catalytic site.
A two-step energy minimization of the CDC25C peptide within a radius
of 6.5 Å around the catalytic site of SYK was carried out using Sybyl6.8
with the AMBER force ﬁeld. The SYK–CDC25C peptide complex struc-
ture was minimized by ﬁrst using the simplex method and then thePowellmethod to the energy gradient b0.05 kcal/(mol·Å). The optimized
parameters were set as follows: the distance-dependent function of the
dielectric constant was adopted, non-bonded cutoff was set to 8 Å, and
Amber charges were applied for the protein and peptide, as described
by Zhang et al. (2005). The SYK–CDC25C peptide complex structure was
minimizedbyﬁrst using the simplexmethodand then thePowellmethod
to the energy gradient b0.05 kcal/(mol·Å).
20 F.M. Uckun et al. / EBioMedicine 1 (2014) 16–282.3. DNA Flow Cytometry
Cells (5 × 105 per mL in plastic tissue culture ﬂasks) were examined
by DNA ﬂow cytometry for emergence of polyploid cells after noco-
dazole exposure using standard procedures. Propidium iodide (PI,
Sigma) was used to determine the percentages of cells in each phase
of the cell cycle by quantitative DNA ﬂow cytometry.
2.4. Establishment of U373 Cells with Ecdysone-Inducible SYK Gene
Expression
U373 cellswere transfectedwith the ecdysone inducible system reg-
ulatory vector, pVgRXR, andwith a pIND/GS vector containing the cDNA
encoding wildtype human SYK gene (H-L28824MI) (Invitrogen) using
published procedures (Supplemental information).
3. Results
3.1. SYK is Localized to Centrosomes and Controls Expression Levels of G2
Checkpoint Genes in Human Cells
By using deconvolution microscopy and high-resolution confocal
laser scanning microscopy, we ﬁrst examined the subcellular localiza-
tion of GFP-tagged recombinant SYK protein in the U373 human glio-
blastoma cell line that was stably transfected with the eukaryotic SYK
expression vector pEGFP-SYK (Fig. 1). In mitotic U373 cells, a signiﬁcant
portion of the overexpressed green-ﬂuorescent recombinant SYK protein
was localized to the mitotic spindle poles on each side of the metaphase
plate and spindle ﬁbers consistent with a centrosomal localization
(Fig. 1c–f). Likewise, SYK was detected in perinuclear centrioles of U373
cells in interphase (Fig. 1g).
The centrosomal localization of SYK taken together with recent pro-
teomic identiﬁcation of several centrosomal proteins (Xue et al., 2012)
as potential kinase substrates of SYK prompted the hypothesis that it
may play an important role in cell cycle regulation. Pon-A Exposure of
SYK-deﬁcient U373 cells stably transfected with wildtype SYK gene
induces expression of SYK and activates downstream signaling
events mimicking oxidative stress-induced activation of SYK and
SYK-dependent signal transduction pathways (Uckun et al., 2010a). In
order to gain insights into the function of SYK as a centrosomal protein,
we ﬁrst examined the effect of SYK expression levels on the expression
levels of cell cycle regulatory genes in human cells using this ecdysone-
inducible mammalian expression system (Uckun et al., 2010a). The eu-
karyotic cell division cycle has been shown to rely on an intricate
sequence of transcriptional events associated with distinct cell cycle reg-
ulated gene expression patterns (Rowicka et al., 2007). Gene set enrich-
ment analysis (GSEA) showed that SYK induction in U373 cells causes a
signiﬁcant down-regulation of evolutionarily conserved genes associated
with mitosis (Fig. 2a, normalized enrichment score:−2.48, false discov-
ery rate b0.0001, P b 0.0001) and cell cycle progression (Fig. 2b, normal-
ized enrichment score:−2.44, false discovery rate b0.0001, P b 0.0001).Fig. 3. Effects of the SYK inhibitor PCT onnocadozole response of a humanB-cell line. [a] Asynchr
0.03 μg/mL (100 nM) NOC for 48 h and then examined byDNA ﬂow cytometry. [b–d] Depicted
cells after 48 h treatment of BCL-1 cells with medium alone (b1–b3), medium supplemente
supplemented with 30 μM PCT +100 nM NOC (d1–d3). System magniﬁcation: 250×. b1, c1:
with midzone microtubules. c2: Cytokinesis. c3. Abnormal metaphase as commonly observed
aligned chromosomes at the metaphase plate 52 ± 5% of BCL-1 cells treated with NOC were
showed a signiﬁcantly higher percentage of cells in metaphase than untreated control cells (
seen in NOC-induced mitotic arrest. d1–d3: Multipolar spindles. 40 ± 5% of BCL-1 cells trea
with bipolar spindles were observed. Multipolar spindles were observed only when BCL-1 cells
pendent experiments and the quantitative data for the % of cells displaying the noted characteris
treatment condition were 57 ± 10 cells in control cultures treated with medium alone, 41 ± 8
treatment. Columns showing the results for interphase cells: Mean ± SE values for percentag
with a large single nucleus, andmultinucleated interphase cells. Columns showing the results fo
anaphase cells with a bipolar spindle, and metaphase/anaphase cells with multipolar spindle
(Dunnett's test, P b 0.001) with chromosome alignment aberrations commonly seen in NOC-
polyploid interphase cells and mitotic cells with abnormal multipolar spindles were observedThe down-regulated genes in SYK-induced U373 cells included the
human homologs of ﬁve yeast genes (viz.: CDC20, TAL1, PGM2, DBF4,
BUB3) (Fig. 2c–e) previously demonstrated to have peak expression in
the G2 andM phases of the yeast cell cycle. Data for the cell cycle speciﬁc
expression of these yeast genes was determined by high-resolution
timing of cell cycle-regulated gene expression based on genome-wide
gene expression data of synchronized yeast cultures (Rowicka et al.,
2007). Among the 53 down-regulated genes, the most signiﬁcantly
affected 10 genes exhibiting the greatest fold-difference values were
PTTG1 (10.4-fold decrease, P = 0.0097), UBEC2C (8.5-fold decrease,
P = 0.0033), CDC20 (8.4-fold decrease, P = 0.002), AURKA (8.3-fold de-
crease, P = 0.0059), CDC25C (7.8-fold decrease ,GSE18798 P = 0.0076),
CCNB1 (7.4-fold decrease, P = 0.0045), CCNB2 (6.8-fold decrease, P =
0.0029), BUB1B (6.4-fold decrease , P = 0.007), BUB1 (5.6-fold decrease,
P =0.0047), and SPAG5 (5.4-fold decrease, P = 0.0178) (accession #:
GSE18798) (Fig. S1). In addition, 15 genes for key regulatory proteins
with anti-proliferative functions such as DUSP1 (3.7-fold increase, P =
0.0005), SEPT4 (1.9-fold increase, P =0.018), SEPT7 (1.7-fold increase,
P = 0.019), and GAS1 (2.4-fold increase, P = 0.034) showed a moderate
increase in expression after SYK induction (Fig. S1). The serine/threonine
kinase ATM, encoded by the Ataxia telangiectasia-mutated (ATM) gene, is
activated by DNA damage (viz.: double-stranded DNA breaks) and is re-
quired for G2 checkpoint activation, which is responsible for inhibition
of G2/M transition following DNA damage (Innes et al., 2006; Stracker
et al., 2008). In this context, ATM signaling delays the entry into mitosis
by causing inactivation of CDC25C and thereby enforces the G2 check-
point. ATM-dependent G2 checkpoint activation in irradiated mouse
cells is associated with down-regulation of a unique group of highly cor-
related genes. Notably, the human homologs ofmany ATM-responsive G2
checkpoint signature genes were also down-regulated by induction of
SYK expression in human U373 cells (Fig. 2f & g). A cluster of 2 genes
(AURKA and CCNB1) showed greater than 5-fold decrease, a cluster of 3
genes (CKS2, GAP43, NCAPD2) showed greater than 3.5-fold decrease
and a cluster of 3 genes (HMGB2, FOXM1, NUDT1) greater than 3-fold de-
crease in expression after SYK induction (Fig. S2). Likewise, a large panel
of radiation-responsive genes that show down-regulation in ATM-
deﬁcient cells, exhibited increased expression levels in SYK-induced
U373 cells, including SERPINA1 that showed a 21.8-fold increase and a
cluster of 12 genes (COL4A5, CXADR, EFNB2, ETV5, GPC4, IGFBP5, IL1R1,
P2RX4, PTPN13, PVRL3, RBMS1, VCAN) with a greater than 2-fold increase
(Fig. S3). Our GSEA also showed that human ATM targets (down-regulat-
ed in irradiatedWT compared to irradiated ATMmutant human lympho-
blasts) (Innes et al., 2006)were overrepresented in genes up-regulated in
irradiated thymocytes from ATM−/− mice (P-value b 0.001,
FDR b 0.001) (Fig. 2h). Human ATM targets were overrepresented in
genes that were down-regulated after SYK induction (P-value = 0.016,
FDR=0.041) providing evidence that SYK induction in U373 cells causes
down-regulation of ATM-dependent human radiation response genes
(Fig. 2I). This immediate response to SYK induction at the transcriptome
level with altered expression of multiple evolutionarily conserved cell
cycle genes served as a strong and compelling early indicator that SYKonously growingEBV-transformedhuman lymphoblastoid B-cell line BCL1was exposed to
are representative two-color Tubulin (green)/DAPI (blue) confocal images of mitotic BCL-1
d with 30 μM PCT (c1, c2), medium supplemented with 100 nM NOC (c3), or medium
Normal metaphase with a bipolar mitotic spindle. b2: Early telophase. b3: Late telophase
in NOC-induced metaphase arrest with lagging chromosomes and absence of correctly
in metaphase arrest. In each of 3 independent experiments, NOC-treated BCL-1 cultures
Dunnett's test, P b 0.001) and exhibited chromosome alignment aberrations commonly
ted with PCT + NOC showed multipolar spindles. No normal metaphases or anaphases
were treated with NOC in the presence of PCT. e. Similar results were obtained in 3 inde-
tics are depicted in bar graphs. The average cell numbers analyzedmicroscopically for each
cells for NOC treatment; 57 ± 5 cells for PCT treatment and 47 ± 5 cells for NOC + PCT
es of interphase cells with a normal size single nucleus, “giant” polyploid interphase cells
rmitotic cells: Mean± SE values for percentages ofmetaphase cells with a bipolar spindle,
s. NOC-treated cultures showed a signiﬁcantly higher percentage of cells in metaphase
induced mitotic arrest. No multinuclear cells were observed in any of the cultures. Giant
only in cells treated with NOC + PCT (**, P b 0.001; Dunnett's test P-value vs CON).
Fig. 4. Effects of the SYK inhibitor PCT on NOC responses of BT20 human breast cancer cells.
Fluorescence (a1–d1) and phase-contrast microscopy (a2–d2) images of BT20 cells in mito-
sis. Systemmagniﬁcation: 250×. Panels e1–e9 depict confocal images of three representative
cells from NOC+ PCT treated cultures stained with α-Tubulin (red), γ-tubulin (green), and
DNA (DAPI, blue). γ-tubulin staining served as a centrosomemarker. Systemmagniﬁcation:
500×.While normal bipolar spindleswere observed inuntreated control or PCT-treatedBT20
cells (a), NOC-treated BT20 cells showed abnormal metaphases with unaligned chromo-
somes congressed at a non-coherent metaphase plate (b). BT20 cells treated with
NOC + PCT showed highly aberrant accumulation of condensed unaligned chromo-
somes in midzone (c) as well as multipolar spindles (e). Similar results were obtained in 3
independent experiments and the quantitative data are shown in Fig. S7, Panel b.
21F.M. Uckun et al. / EBioMedicine 1 (2014) 16–28has a critical and previously unrecognized role inmitotic cell cycle regula-
tion. The down-regulation of the human orthologs of yeast G2/M genes
and human orthologs of ATM-dependent murine G2-checkpoint genes
as well as ATM-dependent human radiation-response genes prompted
the hypothesis that SYK induction may activate a G2 checkpoint
GSE18798 (Accession #: GSE18798).
3.2. Role of SYK as a Kinase that Controls the Cell Cycle in Response to
Microtubule and DNA damage
Treatment of mammalian cells with the microtubule-destabilizing
agent nocodazole (NOC) causes mitotic arrest in the M-phase. When
asynchronously growing EBV-transformed human lymphoblastoid
B-cell line BCL1 was exposed to 0.03 μg/mL (100 nM) NOC for 48 h,
the majority of the cells accumulated with a 4N DNA content, as deter-
mined by DNA ﬂow cytometry (Fig. 3). However, in the presence of the
SYK inhibitor piceattanol (PCT) (30 μM), NOC was unable to effectively
cause anM-phase arrest in BCL1 cells and themajority of these cells ac-
cumulated with a N4N DNA content (Fig. 3a). Confocal immunoﬂuores-
cencemicroscopy of 48 h cultures of BCL-1 cells treatedwithNOC+PCT
showed both mitotic cells with highly aberrant multipolar spindle
formation (Fig. 3d1–d3). Examination of BT20 human breast cancer
cells (Fig. 4) treated with NOC vs. NOC + PCT by ﬂuorescence and
phase-contrast microscopy yielded similar results. The failure of NOC
to cause metaphase arrest in the presence of a SYK inhibitor uniquely
indicated that SYK may control the cell cycle response to microtubule
damage.
We next sought direct and unequivocal genetic evidence for a cell
cycle regulatory role of SYK in lymphoid cells using DT40 chicken
B-cell line and its SYK-deﬁcient DT40 chicken B-cell lymphoma clones
that were established by homologous recombination knockout (Uckun
et al., 1996, 2010a). When asynchronously growing wildtype DT40
cells were exposed to 0.12 μg/mL (400 nM) NOC for 48 h, 56% accumu-
lated with a 4N DNA content and only 19% became polyploid, as deter-
mined by DNA ﬂow cytometry (Fig. 5a1). In contrast to wildtype DT40
cells, only 19% of NOC-treated SYK-deﬁcient DT40 cells had a 4N DNA
content and 61% of these cells continued their DNA synthesis beyond
4Nnuclear DNA content with emergence of 8N nuclei at 48 h and emer-
gence of 8N and 16N nuclei at 72 h (Fig. 5a2). Light microscopic exam-
ination of Wright–Giemsa stained cytospin slides of NOC-treated
wildtype vs. and SYK-deﬁcient DT40 cells showed that more than 50%
of NOC-treated SYK-deﬁcient DT40 cells (but not wildtype DT40 cells)
were very largemononuclear cells with partially decondensed chromo-
somes (Fig. 5, b1 vs. b2). High-resolution confocal microscopy of NOC-
treated cultures of SYK-deﬁcient DT40 cells showed very large mitotic
cells with highly aberrant multipolar spindle formation (Fig. 5, b3 vs.
b4). To further document the signiﬁcance of SYK in cell cycle response
to microtubule damage, we next examined the effects of SYK depletion
by RNAi on NOC response of human 293T cells. SYK-siRNA causes
selective depletion of SYK protein in 293T cells within 72 h, as con-
ﬁrmed byWestern blot analysis (Uckun et al., 2010a, 2012) and con-
focal microscopy (Fig. 5c). Notably, treatment with 50 nM SYK
siRNA (but not scrambled control siRNA) for 72 h prevented NOC
from causing a metaphase arrest and resulted in polyploidy, as
determined by confocal microscopic examination of the size and
DNA content of DAPI-stained nuclei (Fig. 5c). The striking SYK-
dependency of the NOC response in these RNAi experiments further
conﬁrmed that SYK plays a critical role in the regulation of the cell
cycle response to microtubule damage.
3.3. In Situ Physical Interactions Between Native SYK and CDC25C in
Human Cells
Premature hyperactivation of CDC25C in human cancer cells via
phosphorylation on S214, as observed in cells overexpressing low mo-
lecular weight isoforms of cyclin E, has been associated with premature
22 F.M. Uckun et al. / EBioMedicine 1 (2014) 16–28mitotic entry, deregulation of G2-M transition, abrogation of the NOC-
mediated mitotic arrest, centrosome ampliﬁcation with emergence ofcells with supernumerary centrosomes, multipolar anaphase spindles,
chromosome missegregation, and polyploidy due to a cytokinesis failure
(Bagheri-Yarmand et al., 2010a,b). The observed mitotic aberrations in
SYK-deﬁcient cells and cells treatedwith the SYK inhibitor PCTwere rem-
iniscent of the mitotic aberrations reported for cells with hyperactivation
of CDC25C associated with absence of inhibitory S216 phosphorylation
(Bagheri-Yarmand et al., 2010a,b). This prompted the hypothesis that
SYK may act as a negative regulator of CDC25C by controlling its
phosphorylation at S216. Therefore, we next set out to determine if
these two regulatory proteins physically and functionally interact with
each other. We ﬁrst examined if SYK co-localizes with the centrosomal
regulatory protein CDC25C. As evidenced by the confocal merge images
of human BT20 cells depicted in Fig. 6a & b, SYK and CDC25C are co-
localized in cytosol and centrosomes during metaphase and anaphase.
This spatial arrangement of SYK and CDC25C provides a basis for physical
as well as functional interactions. In co-immunoprecipitation experi-
ments, SYK immune complexes contained CDC25C and CDC25C immune
complexes contained SYK (Fig. 6c), providing unprecedented biochemical
evidence for an in vivo physical association between native SYK and
CDC25C in human cells. The detected kinase bands represent kinase
proteins speciﬁcally pulled down by immunoprecipitation or co-
immunoprecipitation as no SYK or CDC25C proteins were detected by
Western blot analysis when no primary anti-SYK or anti-CDC25C an-
tibodies were added to the immunoprecipitation mixtures.
3.4. SYK Phosphorylates CDC25C on Serine 216
The primary phosphorylation site of CDC25C involved in G2 check-
point control is at its S216 residue in humans and S287 residue in
Xenopus (Perry and Kornbluth, 2007; Donzelli and Draetta, 2003;
Kumagai and Dunphy, 1999). This residue is phosphorylated through-
out interphase but not in mitosis and it is known to control the timing
of mitosis. The S216 phosphorylated CDC25C binds to members of theFig. 5. SYK gene is required for nocodazole-induced mitotic arrest. [a &b] DT40 chicken
lymphoma B-cells were treated with NOC (0.12 μg/mL × 48 h at 37 °C) and then exam-
ined by DNA ﬂow cytometry for emergence of polyploid cells. The decimal points for the
percentages of nuclei with deﬁned DNA content were rounded off in the depicted DNA
histograms. [a.1] Wildtype DT40 cells that showed accumulation in G2/M after NOC treat-
ment. The percentages of 2N, 4N and N4N nuclei were 8.1%, 56.2%, and 19.3%, respectively
and % of cells in S-phase was 16.3%. [a.2] A substantial proportion of SYK-deﬁcient DT40
cells whichwere established by homologous recombination knockout, showed only a par-
tial accumulation of cells with a 4NDNA contentwhen treatedwith nocodazole, and N50%
of these cells continued their DNA synthesis beyond4NnuclearDNA content. The aberrant
DNA synthesis continued after cells were washed to remove NOC at 48 h with 68% of the
cells showing 8N–16NDNA content at 72 h. At 72 h, 1.7% of untreated SYK-deﬁcient DT40
cells had hypodiploid/apoptotic nuclei that are not included in the DNA histogram. [b.1 &
b.2] Morphologic features of Nocodazole-treated SYK-Deﬁcient DT40 cells. Wright–
Giemsa stained cytospin slides of NOC-treated wildtype (b1) and SYK-deﬁcient (b.2)
cells were examined by light microscopy at 48 h post NOC exposure. More than 50% of
NOC-treated SYK-deﬁcient DT40 cells (but not wildtype DT40 cells) were very large
mononuclear cells with partially decondensed chromosomes. System magniﬁcation:
100×. [b3 & b4] Confocal two-color ﬂuorescencemerge image of a representative untreat-
edwildtypeDT40 cell inmetaphasewith a bipolarmitotic spindle (b3) vs. a representative
NOC-treated polyploid SYK-deﬁcient (b4) DT40 cell with abnormal multipolar spindles.
The images were obtained following a 48 h treatment with 0.12 μg/ml NOC.
Green = Tubulin; blue = TOTO-3 stained DNA/Chromosomes (system magniﬁcation:
500×). [c] siRNA-induced depletion of native SYK causes polyploidy in Nocodazole-treated
293T cells. Confocal images of 293T cells stained with the ﬂuorescent DNA dye 4′,6-
diamidino-2-phenylindole (DAPI) (blue) and anti-SYK antibody (green) after 72 h of RNAi
via transfection with SYK-siRNA or scrambled(scr)-siRNA (included as a control) and 48 h
of treatment with 400 nM NOC (i.e. 120 h after the start of the RNAi.). Each siRNA was
used at a 50 nM concentration. A no treatment control (CON) was also included. Twelve of
12 control 293T cells showed abundant SYK staining and normal size nuclei (c1). Six of 12
scr-siRNA transfected, NOC-treated 293T cells showed enlarged nuclei and abundant SYK
expression (c2). The remainder of the scr-siRNA transfected, NOC-treated 293T cells had a
normal size nucleus. Eight of 20 SYK-siRNA transfected 293T cells became polyploid after
NOC exposure with very large nuclei and profoundly diminished SYK expression due to
siRNA-mediated SYK depletion (c3 & c4). The remainder of the SYK-siRNA treated cells
had an enlarged nucleus and profoundly diminished SYK expression due to siRNA-mediated
SYK depletion (systemmagniﬁcation: 600×).
Fig. 6. Centrosomal co-localization and physical interactions of native SYK and CDC25C proteins in human cells. [a & b] Subcellular co-localization of SYK and CDC25C during mitosis.
Log-phase BT20 cells growing in culture were ﬁxed and stained with either anti-SYK (red) or anti-CDC25C (green) antibodies. Cellular DNA was labeled in all slides with TOTO-3
(Blue). Depicted are representative cells in metaphase (a) or anaphase (b) showing subcellular localization of SYK and CDC25C. Merge confocal images document co-localization of
SYK and CDC25C as “yellow” immunoﬂuorescent foci. Chromosomes at the metaphase plate show blue ﬂuorescence because of TOTO-3 labeled DNA. System magniﬁcation: 500×. [c]
In Situ Association of SYK and CDC25C. [c1] CDC25C Western blot analysis of SYK and CDC25C immune complexes. SYK (lane 1) and CDC25C (lane 2) immune complexes
immunoprecipitated from human LOUCY cell line were subjected to CDC25C Western blot analysis. [c2] SYK Western blot analysis of SYK and CDC25C immune complexes. The same
SYK and CDC25C immune complexes immunoprecipitated from LOUCY cells that were examined by CDC25CWestern blot analysis as depicted in Panel c1were subjected to SYKWestern
blot analysis. The positions of CDC25C (predicted size: 53 kDa), SYK (predicted size: 72 kDa), a degradation product of native SYK (SYK-DP) as well as the positions for the denatured
heavy chain (IgG HC, 55 kDa) and light chain (IgG LC, 22 kDa) fragments of the immunoprecipitating anti-bodies are indicated with arrowheads.
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Dunphy, 1999). The cytoplasmic retention of CDC25C prevents it from
activating CDK1 by Y15 and T14 dephosphorylation. We performed
in vitro kinase assays to experimentally determine if recombinant SYK
can phosphorylate theGST-taggedXenopus CDC25C (245–316) peptide
containing S287 that corresponds to the S216 residue of human
CDC25C. This peptide also contains a single tyrosine residue (283 in
Xenopus and 212 in human) located at the −4 position with respect
to S287 (YRSPSMP). SYK phosphorylated the wildtype CDC25C peptide
and a phosphoaminoacid analysis of the SYK-phosphorylated CDC25C
peptide showed that the phosphorylation occurred on serine (Fig. 7a.1
& a.2). Notably, recombinant SYK was able to phosphorylate the
Y283A mutant form (“YMT”) of the CDC25C peptide but not its S287A
mutant form (“SMT”) (Fig. 7a.1). We next performed in vitro kinase
assays to determine if puriﬁed recombinant SYK can phosphorylate a
GST-tagged full-length recombinant human CDC25C protein on S216
residue. A matrix-assisted laser desorption/ionization–time-of-ﬂight
(MALDI-TOF)/TOF mass spectrometry analysis was performed on
trypsin-digested recombinant CDC25C after an in vitro kinase reaction
with recombinant SYK. After TiO2 enrichment, a precursor with a mass
of 1477.68 Da corresponding to the peptide 214SPSMPENLNRPR225 con-
taining the S216 phosphoepitope in phoshorylated form was identiﬁed
(Fig. 7b). TheWestern blot analysis of the CDC25C protein from the SYK
plus CDC25C kinase reaction mixtures with a phosphospeciﬁc antibody
that recognizes S216-phosphorylated CDC25C showed markedly en-
hanced S216 phosphorylation (Fig. 7c–e). Having conﬁrmed the ability
of recombinant puriﬁed SYK to phosphorylate CDC25C on the inhib-
itory residue S216 in vitro, we next examined the regulatory role of
SYK in CDC25C phosphorylation in vivo using an ecdysone-inducible
mammalian expression system (Uckun et al., 2010a). Pon-A expo-
sure of SYK-deﬁcient U373 cells stably transfected with wildtype
human syk gene induced expression of SYK within 24 h (Fig. 7f).
SYK induction without any exposure to NOC was sufﬁcient for acti-
vating S216-phosphorylation of CDC25C, as determined by Western
blot analysis using a CDC25Cphos-S216 speciﬁc antibody (Fig. 7h). We
next examined the effects of RNAi-mediated SYK depletion on the NOC-
triggered S216 phosphorylation of CDC25C in 293T cells. Treatment of
human 293T cells with NOC triggered phosphorylation of CDC25C on
the inhibitory S216 residue (Fig. 8). SYK siRNA abrogated the NOC-
induced S216-phosphorylation of CDC25C, whereas treatment with
scrambled siRNA (included as a negative control) had no such effect(Fig. 8 a & d). These results demonstrate that SYK is required for S216
phosphorylation of native CDC25C in vivo after NOC exposure and pro-
vide compelling support for the notion that native CDC25C in human
cells is not only physically associated with SYK, but it also serves as an
in vivo kinase substrate for native SYK.
We constructed a structural model of a complex between SYK and
the CDC25C peptide Leu-Tyr-Arg-Ser-Pro-Ser-Met-Pro-Glu (residues
211–219) to evaluate the molecular mechanism for the ability of SYK
to phosphorylate CDC25C on S216. This model posits that the target
CDC25C peptide would readily bind to SYK catalytic site with a compact
conformation due to its narrow and deep shape (Fig. 9A). Because of
space constraints, the small S216 residue is more likely to ﬁt the hydro-
phobic pocket created by the activation loop containing the DFG motif
(Asp512-Phe513-Gly514) than the larger Y212 residue.
4. Discussion
The activity of centrosomal CDK1 plays a crucial role in the regula-
tion of mitotic timing. RNAi-mediated depletion of centrosomal CDK1
or CEP63 that recruits CDK1 to centrosomes causes accumulation of
“giant cells” due to polyploidization through mitotic skipping (Löfﬂer
et al., 2011). Before mitosis, CDK1 is kept in an inactive state via phos-
phorylation at T14 and Y15, which is catalyzed by the protein kinases
WEE1 and MYT1 (Lindqvist et al., 2009). CDK1 activation, on entry
into mitosis, results from simultaneous inhibition of WEE1 and MYT1
and activation of CDC25C. Any corruption of this regulatory process of
activation and inactivation of CDK1 can trigger mitotic defects. The G2
checkpoint prevents CDC25C phosphatase from removing the T14/Y15
phosphate groups on CDK1 and thereby provides more time for DNA
damage repair prior to mitotic entry. This is accomplished by maintain-
ing CDC25C in an inactive S216-phosphorylated form. Our ﬁndings
presented herein provide the ﬁrst genetic and biochemical evidence
for a previously unknown function of SYK as a cell cycle regulatory ki-
nase that phosphorylates CDC25C at S216. This unique role of SYK as a
cell cycle checkpoint regulator may represent a signiﬁcant challenge
for SYK inhibitors that are being developed for various indications.
Homozygous CDC25C knockout (CDC25C−/−) mice are viable,
fertile, develop normally and do not have an obvious phenotype
(Chen et al., 2001; Lee et al., 2011). These ﬁndings indicate that the re-
lated protein phosphatases CDC25A and/or CDC25B may compensate
for loss of CDC25C in the mouse (Chen et al., 2001; Lee et al., 2011).
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cient to cause mitotic aberrations. In particular, a premature activation
of CDC25C by S214 phosphorylation, which renders it resistant to inhib-
itory S216 phosphorylation, can cause dephosphorylation of CDK1 on
T14 and Y15, thereby activatingCDK1 andpromotingprematuremitotic
entry (Bagheri-Yarmand et al., 2010b). Premature hyperactivation of
CDC25C in human cancer cells via phosphorylation on S214, as observed
in cells overexpressing low molecular weight isoforms of cyclin E, hasindeed been associated with premature mitotic entry, deregulation of
G2-M transition, abrogation of the NOC-mediated mitotic arrest, emer-
gence of centrosome ampliﬁcation with emergence of cells with super-
numerary centrosomes, multipolar anaphase spindles, chromosome
missegregation, and polyploidy due to a cytokinesis failure (Bagheri-
Yarmand et al., 2010b). CDC25C has been shown to mediate these
mitotic aberrations because they are abrogated by RNAi-induced deple-
tion of CDC25C (Bagheri-Yarmand et al., 2010b). Notably, cells rendered
SYK-deﬁcient by homologous recombination knockout or RNAi of the
SYK gene as well as functionally SYK-deﬁcient cells treated with the
SYK inhibitor PCT displayed G2 checkpoint abnormalities reminiscent
of the aforementioned mitotic aberrations reported for cells with
CDC25Chyperactivateddue to resistance to S216phosphorylation. In par-
ticular, SYK-speciﬁc siRNA as well as SYK inhibitor PCT were effective in
overriding a checkpoint-dependentmitotic arrest provokedbyNOC treat-
ment in both B-lineage lymphoid and non-lymphohematopoietic human
cells. The documented ability of SYK to phosphorylate CDC25C on S216
provided a cogent explanation for this phenotype associated with SYK-
deﬁciency and uniquely indicated that other kinases capable of S216
phosphorylation, are unable to compensate for SYK deﬁciency. SYK thus
appears to be an essential component of a cell cycle regulatory surveil-
lance system in human cells.
Human polo-like kinase (PLK) physically associates with SYK at the
mitotic spindle poles (Uckun et al., 2010b). In the context of oxidative
stress, PLK has been shown to activate SYK by phosphorylating it on
T524 residue, which is located in a critical position on the turn of the
hairpin structure of the activation (A)-loop of the SYK kinase domain
in close relationship to the activation residues Y519/Y520 (UckunFig. 7. SYK phosphorylates CDC25C on serine 216. [a.1] In vitro phoshorylation of Serine
287 residue (corresponding to Serine 216 in human CDC25C) within the Xenopus GST-
CDC25C peptide (254–316) by puriﬁed recombinant SYK. 1 mg of wildtype and mutant
GST-CDC25C peptideswere used as potential substrates in hot kinase assays using 1 μg re-
combinantmurine SYK in thepresence of 1mCi of [γ-32P]ATP (Lanes 2–4). In control sam-
ple (Lane 1), 10 μg of recombinant SYK was allowed to autophosphorylate in the absence
of GST-CDC25C peptide. The reaction mixtures were subjected to gel electrophoresis
followed by autoradiography. Arrowheads indicate the positions of autophosphorylated
SYK and phosphorylated GST-CDC25C peptides. Mutation of the S287 residue within the
sequence of 254–316 of GST-CDC25C peptide to alanine abolished the phosphorylation
detected on SYK-treated wildtype GST-CDC25C peptide (Lane 3 vs. Lane 2). By contrast,
the mutation of Y283, which is the only tyrosine residue within the sequence of
254–316 of GST-CDC25C peptide to alanine did not affect its SYK-mediated phosphoryla-
tion (Lane 4). [a.2] Phospho amino acid analysis of the SYK phosphorylatedwildtype GST-
CDC25C peptide showed phosphorylation on serine. The 32P-labeled GST-CDC25C band in
[A, Lane 2] was isolated and subjected to PAA. The positions of ninhydrin-stained
phosphoamino acid standards (phosphoserine [S], phosphothreonine [T], and phos-
photyrosine [Y]) are indicatedwith circles. [b]MALDI-TOF peptideMS of the tryptic digest
of SYK-phosphorylated recombinant human CDC25C protein. The 1477.68 Da ion corre-
sponds to single site (98 Da) phosphorylation of the 214SPSMPENLNRPR225 peptide con-
taining the S216 residue that has one phosphate loss. Subsequent CID spectra revealed a
peak at 1379.90 Da corresponding to a mass loss of 98 Da. [c–e] Puriﬁed recombinant
SYK phosphorylates recombinant human full-length CDC25C protein on Serine 216.
GST-tagged recombinant human CDC25C was treated with recombinant SYK in a cold
kinase assay to determine if it can be phosphorylated by SYK. Western blot analysis of
SYK-phosphorylated vs. control CDC25C protein with a phosphospeciﬁc antibody recog-
nizing S216-phosphorylated CDC25C showed that recombinant SYK phosphorylates
recombinant CDC25C on S216. The position of the S216-phosphorylated 83 kDa GST-
tagged full-length CDC25C protein is denoted with an arrowhead (Panel c). Western
blot analysis of the kinase assay mixtures with anti-CDC25C antibody showed near
equal amounts of substrate protein in control and test samples. In addition to the intact
83 kDa protein, 55 kDa and 37 kDa proteolytic cleaved forms of GST-CDC25C are also
seen in this commercial preparation (Panel d). The presence of SYK (predicted size:
72 kDa) in the kinase assay mixtures containing recombinant murine SYK was conﬁrmed
by anti-SYK Western blot analysis (Panel e). [f–h] In vivo S216 phosphorylation of native
human CDC25C in an ecdysone-inducible mammalian expression system for human SYK.
Panel f shows the anti-SYKWestern blot analysis of whole cell lysates of untransfected vs.
transfectedU373 cells before and 24–48 h after exposure to the ecdysone-analogue Pon-A
(10 μM). SYK protein (72–75 kDa, predicted size: 72 kDa) is detected in lysates of PonA
treated cells. Panel g depicts the results of anti-CDC25C Western blot analysis of control
SYK− vs. Pon(A) treated SYK+ cells showing similar levels of native CDC25C protein
(55 kDa, predicted size: 53 kDa) irrespective of SYK induction. Panel h shows that SYK
induction causes S216 phosphorylation of native CDC25C protein, as detected byWestern
blot analysis using a highly speciﬁc antibody directed against the CDC25C phospho-
epitope S216.
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studies, PLK-induced phosphorylation of SYK on T524would unlock the
tangled inhibitory conformation of A-loop and promote the phosphory-
lation of the activation residues Y519/Y520 (Uckun et al., 2010b). The
physiologic role of PLK-induced SYK activation may be to enhance the
survival of cells challenged with oxidative stress-associated DNA dam-
age by evoking an anti-apoptotic response via activation of SYK and
SYK-dependent NFκB, PI3-K/AKT, and STAT3 signal transduction path-
ways (Uckun and Qazi, 2010). As an M-phase speciﬁc serine/threonine
kinase, PLK regulates CDK1 function via phosphorylation and activation
of CDC25C (Wang et al., 2009; Bonni et al., 2008; Roshak et al., 2000; Xie
et al., 2005; Bahassi et al., 2004). CDC25C is predominantly cytoplasmic
and its nuclear import is triggered by PLK-induced phosphorylation of
S191 and S198 residues within an N-terminal functional nuclear exclu-
sion motif (Wang et al., 2009; Roshak et al., 2000; Xie et al., 2005;
Bahassi et al., 2004). We propose that a negative feedback loop exists
between PLK and SYK that rapidly limits the pro-mitotic signal of PLK
via inhibitory S216 phosphorylation of CDC25C by PLK-activated SYK
in cells exposed to oxidative stress (Fig. 9B). The previously unrecog-
nized function of SYK as a regulator of G2 checkpoint may serve as a
physiologically important backup regulatory surveillance system forFig. 8. siRNA-mediated depletion of Native SYK prevents nocodazole-induced S216-
phosphorylation of native CDC25C in human cells. [a–c] Anti-CDC25C(pS216),
anti-CDC25C, and anti-GRP78 Western blot analysis of whole cell lysates from 293T cells
treated with medium only (CON), SYK-siRNA or scr-siRNA that was used as a control.
NOC treatment (0.1 μg/mL) for 24 h induced S216 phosphorylation of native CDC25C
(Panel a, Lane 2 vs. Lane 1) without a change in the levels of CDC25C or GRP78 proteins
(Lane 2 vs. 1, Panels b & c). SYK-siRNA abrogated NOC-induced S216 phosphorylation of
CDC25C (Panel a, Lane 4 vs. Lane 3). By contrast, scr-siRNA did not block NOC-induced
S216 phosphorylation of CDC25C (Panel a, Lane 6 vs. Lane 5). [d & e] Depicted are the re-
sults of a repeat analysis of SYK-siRNA effects on NOC-induced CDC25C phosphorylation
on S216. Anti-CDC25C(pS216) (Panel d) and anti-cdc2/Cdk1 (Panel e) Western blot
analysis ofwhole cell lysates from 293T cells treatedwithmediumonly (CON), SYK-siRNA
or scr-siRNA that was used as a control showed that NOC treatment induced S216 phos-
phorylation of native CDC25C (Panel d, Lane 2 vs. Lane 1) without a change in the levels
of Cdc2/Cdk1 (Panel e, Lane 2 vs. Lane 1). SYK siRNA abrogated NOC-induced S216 phos-
phorylation of CDC25C (Panel d, Lane 4 vs. Lane 3). By contrast, scr-siRNA did not block
NOC-induced S216 phosphorylation of CDC25C (Panel d, Lane 6 vs. Lane 5). In a-e, each
siRNA was used at a 50 nM concentration.DNAdamage and complement the functions of other checkpoint regula-
tors by preventing the reinitiation of DNA synthesis before themitosis is
correctly completed or DNA damage is repaired. The presented evi-
dence for the existence of a cell cycle checkpoint regulatory function
of SYK that controls DNA replication extends previous studies respect-
ing the involvement of protein kinases in cell cycle regulation as well
as studies on the pleiotropic biologic effects of SYK kinase-linked bio-
chemical signals.
Spleen tyrosine kinase (SYK) is a physiologically important ki-
nase that serves as a key regulator of multiple biochemical signal
transduction events and biologic responses in B-lineage lymphoid
cells throughout B-cell ontogeny (Cheng et al., 1995; Mocsai et al.,
2010; Turner et al., 1997; Uckun and Qazi, 2010; Zhou et al.,
2006). SYK deﬁciency is associated with pro-B cell leukemia in in-
fants (Goodman et al., 2001). Recently SYK has been identiﬁed as a
dual-speciﬁcity kinase that not only phosphorylates tyrosine but
also serine (S) residues (Heizmann and Reth, 2010). SYK also has
important functions in BCR-independent signaling pathways in
lymphohematopoietic as well as non-lymphohematopoietic cells
(Uckun and Qazi, 2010; Zhou et al., 2006; Goodman et al., 2001;
Heizmann and Reth, 2010; Wang et al., 2005; Uckun et al., 2010a,
2012). As a regulatory tyrosine kinase, SYK plays an important and
indispensable role in oxidative stress-induced activation of the anti-
apoptotic transcription factor STAT3 via tyrosine phosphorylation and
its catalytic domain is critical for this survival-promoting function
(Uckun et al., 2010a). Homozygous syk knockout mice suffer severe
hemorrhaging as embryos and virtually all die at midgestation or perina-
tally due to lymphatic hyperproliferation, vascular defects and blood-
lymphatic shunts (Cheng et al., 1995; Böhmer et al., 2010; Abtahian
et al., 2003). SYK tyrosine kinase has also been identiﬁed as a mitotic
kinase that localizes to the centrosomes (Uckun et al., 2010b; Navara
et al., 1999; Xue et al., 2012; Zyss et al., 2005) and affects mitotic progres-
sion (Heet al., 2002; Zyss et al., 2005). Several candidate centrosomal sub-
strates for SYK were identiﬁed by using sensitive kinase assays linked
with phosphoproteomics, supporting a unique mechanism whereby
SYKnegatively affects cell division through its centrosomal kinase activity
(Xue et al., 2012).
The activity of centrosomal CDK1 plays a crucial role in the regula-
tion of mitotic timing. RNAi-mediated depletion of centrosomal CDK1
or CEP63 that recruits CDK1 to centrosomes causes accumulation of
“giant cells” due to polyploidization through mitotic skipping (Löfﬂer
et al., 2011). Before mitosis, CDK1 is kept in an inactive state via phos-
phorylation at T14 and Y15, which is catalyzed by the protein kinases
WEE1 and MYT1 (Lindqvist et al., 2009). CDK1 activation, on entry into
mitosis, results from simultaneous inhibition of WEE1 and MYT1 and ac-
tivation of CDC25C. Any corruption of this regulatory process of activation
and inactivation of CDK1 can trigger mitotic defects. The G2 checkpoint
prevents CDC25C phosphatase from removing the T14/Y15 phosphate
groups on CDK1 and thereby provides more time for DNA damage repair
prior to mitotic entry. This is accomplished by maintaining CDC25C in an
inactive S216-phosphorylated form. Our ﬁndings reported herein provid-
ed both genetic andbiochemical evidence for a previously unknown func-
tion of SYK as a cell cycle regulatory kinase that phosphorylates CDC25C at
S216. Hence, SYK was discovered as an inhibitor of CDC25C which pre-
vents premature entry into mitosis by phosphorylating CDC25C at S216
when G2 checkpoint responses are activated. Notably, SYK induction
was associated with marked changes in the cell cycle related tran-
scriptome. Gene set enrichment analysis showed that SYK induction in
human cells causes a signiﬁcant down-regulation of evolutionarily con-
servedgenes associatedwithmitosis and cell cycle progression, indicating
that SYK induction likely delays the mitotic entry. The down-regulated
genes in SYK-induced cells included the human homologs of 3 yeast
genes (viz.: CDC20, DBF4, BUB3) previously demonstrated to have peak
expression in theMphase of the yeast cell cycle (Rowicka et al., 2007). In-
activation of CDC25C by ATM signaling triggered by DNA damage (Innes
et al., 2006; Stracker et al., 2008) has been shown to be associated with
Fig. 9. SYK as a negative regulator of CDC25C [A] molecular surface of SYK kinasewithmodeled CDC25C peptide. The DFGmotif in catalytic site of SYK (Asp512-Phe513-Gly514) is shown
as stickmodel. Themolecular surface of SYK is colored by atom type: carbon in gray, oxygen in red, nitrogen in blue, and sulfur in yellow. Substrate peptide (Leu-Tyr-Arg-Ser-Pro-Ser-Met-
Pro-Glu, residues 211–219 of human CDC25C) is shown as stick model and color-coded by atom type: carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow. The ﬁgure was prepared
with PyMOL Molecular Graphics System (version ro.99, Schrodinger LLC). According to this model, the 9-amino acid CDC25C peptide binds in an extended conformation to the catalytic
groove on the surface of SYK and interacts with its N- and C-terminal subdomains. The Ser216 residue of the substrate CDC25C peptide is hydrogen bonded with the conserved Asp512
residue of SYK that serves as the catalytic base to accept the proton from Ser216. The Ser214 and Arg213 residues of the CDC25C peptide formhydrogen bondswith theArg498 and Ser511
residues of SYK. [B] Amodel of Cell cycle regulation in the context of oxidative stress and DNA damage. In response to oxidative stress or DNA damage, the ATM/ATR signaling pathway is
activated leading to downstream activation of CHK1 and CHK2 kinases that phosphorylate CDC25C on S216. S216 phosphorylation of CDC25C has been shown to inhibit its CDK1-activating
function in the nucleus by enhancing its binding to 14-3-3 proteins and thereby causing its sequestration in the cytoplasm. We propose that a negative feedback loop exists between PLK
and SYK that rapidly limits the pro-mitotic signal of PLK by inhibitory S216 phosphorylation of CDC25C by PLK-activated SYK in cells exposed to oxidative stress. This previously unrecognized
function of SYKmay serve as a physiologically important backup regulatory surveillance system forDNAdamage and complement the functions of other checkpoint regulators bypreventing the
reinitiation of DNA synthesis before the mitosis is correctly completed or DNA damage is repaired.
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nature genes and those genes are upregulated in ATM-deﬁcient mouse
cells. Notably, the human homologs of these genes were also downregu-
lated by induction of SYK expression in human cells. The down-regulation
of the human orthologs of yeast M-phase genes and human orthologs of
ATM-dependent murine G2-checkpoint genes as well as ATM-dependent
human radiation-response genes supports the model that SYK induction
activates a G2 checkpoint and thereby delays mitotic entry.
The identiﬁcation of SYK as a master regulator of anti-apoptotic sig-
naling in B-lineage leukemia/lymphoma cells prompted the develop-
ment of SYK inhibitors as a new class of anti-cancer drug candidates
(Uckun and Qazi, 2010; D'Cruz and Uckun, 2012; Myers et al., 2014;Uckun et al., 2013; Perova et al., 2014; Wang et al., 2014; Geahlen,
2014). However, the discovery that SYK is a dual-function kinase with
important tumor suppressive and cell cycle regulatory roles represents
a new and unexpected challenge for the translational research efforts.
SYK has been previously shown to play an important tumor suppressor
function during human lymphocyte ontogeny by protecting the lym-
phoid progenitors from a leukemogenic CK2-mediated inhibition of
Ikaros function (Uckun et al., 2012). Furthermore, SYK-induced serine
phosphorylation is required for the ability of IK to mediate the differen-
tiation of human B-cell precursors (Uckun et al., 2012). Indeed, defec-
tive SYK expression has been implicated in the pathogenesis of infant
pro-B cell acute lymphoblastic leukemia (ALL) (Goodman et al., 2001),
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arrest at the pro-B cell stage and is associated with poor prognosis.
Notably, B-cell precursors from infant patients with pro-B cell leukemia
have markedly reduced SYK activity due to expression of defective SYK
proteins with a missing or truncated catalytic kinase domain coded by
profoundly aberrant mRNA species (Goodman et al., 2001). This associ-
ation between SYK deﬁciency and development of aggressive pro-B cell
leukemia in infancy may be caused by a loss of SYK-induced phosphor-
ylation of IK on activating serine residues S358 and S361 (Uckun et al.,
2012). Consequently, the use of kinase inhibitors of the conserved ATP
binding site within the catalytic domain of SYK, which is required for
both its tyrosine kinase activity and serine kinase activity, as are most
SYK inhibitors in preclinical or clinical development (D'Cruz and
Uckun, 2012; Perova et al., 2014; Geahlen, 2014), including compound
R406 and its pro-drug R788 (Fostamatinib disodium/FosD), may con-
tribute to an increased risk of emergence of new leukemic clones and
progression of leukemia, especially in pediatric leukemia patients who
are subjected to DNA damaging agents as part of their multi-modality
standard treatment programs. Furthermore, because of the similarities
of the ATP pocket structures among different kinases, most of these in-
hibitors affect multiple tyrosine kinases and have off-target activities
(D'Cruz and Uckun, 2012). Indeed hypertension, a common and poten-
tially dangerous side effect of FosD, has been attributed to off-target in-
hibition of VEGFR (D'Cruz and Uckun, 2012). Inhibitors targeting the
substrate binding sites of tyrosine kinases are hoped to have enhanced
speciﬁcity and potency (Uckun et al., 2010a; Myers et al., 2014; Uckun
et al., 2013). The selective inhibition of anti-apoptotic tyrosine phos-
phorylation events by blocking the binding of the substrates of SYK
(rather than inhibiting theATPbinding site)would not cause amalfunc-
tion of Ikaros because it spares the ATP site-dependent serine kinase
function of SYK. Therefore, it will be very important to develop selective
inhibitors of the tyrosine kinase substrate binding (P)-site of SYK.
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